XTX202 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05052268

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05052268. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 6:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202 in Patients with Advanced Solid Tumors

Study identification

NCT ID: NCT05052268
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Xilio Development, Inc.; Industry
Enrollment: 95 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

XTX202 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 18, 2022 (Actual)
Primary completion: Mar 22, 2025 (Actual)
Completion: Mar 25, 2025 (Actual)
Last update posted: May 28, 2026

2022 – 2025

United States locations

U.S. sites: 15
U.S. states: 11
U.S. cities: 14

Facility	City	State	ZIP	Site status
UC San Diego Moores Cancer Center	La Jolla	California	92093	—
Norris Comprehensive Cancer Center	Los Angeles	California	90033	—
University of California Los Angeles	Los Angeles	California	90095	—
Hoag Memorial Hospital Presbyterian- Newport Beach	Newport Beach	California	92663	—
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	—
Moffitt Cancer Center	Tampa	Florida	33612	—
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
HealthPartners Cancer Center at Regions Hospital	Saint Paul	Minnesota	55101	—
Atlantic Health System/Morristown Medical Center	Morristown	New Jersey	07960	—
Rutgers Cancer Institute of NJ	New Brunswick	New Jersey	08903	—
Carolina BioOncology Institute	Huntersville	North Carolina	28078	—
The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute	Columbus	Ohio	43210	—
UPMC Hillman Cancer Center Pavilion	Pittsburgh	Pennsylvania	15213	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05052268, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 28, 2026 · Synced Nov 14, 2026